Physician profile
Johny E Fares
NPI 1942761051
$1,069.47
in general payments reported to CMS, 2019-2025
11 companies · $543 in 2025
The $543 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $139 · 2021: $152 · 2024: $235 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $777.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $195.17 | 2024-2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $170.20 | 2021-2025 | Saphnelo |
| Abbvie INC. | $140.38 | 2020-2024 | |
| Amgen INC. | $137.54 | 2024-2025 | Evenity, Prolia, Otezla |
| Alexion Pharmaceuticals, INC. | $128.00 | 2025 | Ultomiris |
| Pfizer INC. | $73.08 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $66.12 | 2025 | |
| Aurinia Pharma U.S., INC. | $52.93 | 2025 | Lupkynis |
| Glaxosmithkline, LLC. | $41.12 | 2024-2025 | Benlysta |
| Lilly USA, LLC | $40.60 | 2025 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johny Fares listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.